Clinical Trial Update: Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial update for G/P +/- RBV in previously treated genotype 1 hepatitis C patients completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• G/P (glecaprevir/pibrentasvir)
• RBV (ribavirin)

Snippet

Sponsor: University of Florida | Conditions: Hepatitis C, HCV | Phase 3 | Status: COMPLETED | Results posted: 2020-02-05